You are here » Home » Companies » Company Overview » FDC Ltd

FDC Ltd.

BSE: 531599 Sector: Health care
NSE: FDC ISIN Code: INE258B01022
BSE 00:00 | 19 Feb 238.95 0
(0.00%)
OPEN

246.00

HIGH

248.00

LOW

237.00

NSE 00:00 | 19 Feb 239.15 0.30
(0.13%)
OPEN

240.30

HIGH

248.85

LOW

237.10

OPEN 246.00
PREVIOUS CLOSE 238.95
VOLUME 5761
52-Week high 265.00
52-Week low 148.20
P/E 18.13
Mkt Cap.(Rs cr) 4,086
Buy Price 236.30
Buy Qty 500.00
Sell Price 246.00
Sell Qty 21.00
OPEN 246.00
CLOSE 238.95
VOLUME 5761
52-Week high 265.00
52-Week low 148.20
P/E 18.13
Mkt Cap.(Rs cr) 4,086
Buy Price 236.30
Buy Qty 500.00
Sell Price 246.00
Sell Qty 21.00

FDC Ltd. (FDC) - Chairman Speech

Company chairman speech

FDC LIMITED ANNUAL REPORT 2005-2006 CHAIRMAN'S REPORT CHAIRMAN'S MESSAGE Dear Shareowners, Your Company has, over the years, been known for its trend setting standards in the Indian pharmaceutical market. All along it has offered innovative dosage forms at affordable prices, especially in the segments of ophthalmics, pediatrics, infant diarrhoea, lactose intolerance, and dermatologicals. Moreover, in the last 5 years, its anti-infective range of Cephalosporin dosage forms have achieved prominent ORG rankings by gaining substantial market share and brand equity in record time. Being the first Indian Company to get the U.K. MHRA approval to manufacture sterile ophthalmic dosage forms in India, FDC has garnered significant market share in the U.K., for its ophthalmic range anti-infectives, anti- glaucoma, and viscolizers. Soon your Company will get regulatory clearances for a few more ophthalmic products in the U.K., including an anti-allergic and a new anti-glaucoma dosage form. Similar marketing authorizations are expected, and will result in meaningful revenues from other countries in the European Union. With the approval of the ANVISA (Brazilian Regulatory Authority), our ophthalmic facility at Waluj will shortly begin to supply ophthalmics to the Brazilian market with a long-term objective to cater to many more Latin American countries. In addition, our launch of ophthalmics in the U.S. is in its final stage. With six ANDA's near approval, we are exploring marketing options in the U.S. With the Patent regime in place, you will be pleased to note that your Company has collaborated with renowned ophthalmologists to develop a novel single-dose unit (UNIMS), which was launched in India in June 2006. Apart from patenting and marketing this product in India, this product will soon be marketed worldwide, after we comply with the Regulatory requirements of various countries. As a progressive Company, FDC is making efforts to develop New Chemical Entities (NCE's). As a result, a number of new structures in the field of anti-fungals are at various stages of evaluation. Few of these structures will be patentable as well as valuable. Moreover, we have developed in- house capabilities to perform studies on the anti-bacterial activities of these compounds. Our new State-of-the-art facility to manufacture Cephalosporin dosage forms at Baddi, Himachal Pradesh, will commence operations in July 2006. This facility is built on a global scale, and is geared to meet international quality standards. Your Company's biotechnology R&D scientists have developed, in-house, various mammalian cell lines, which will help us to screen new molecules in the field of ophthalmology, further strengthening our research capabilities. By leveraging the following strengths: 1. Well established brands in several segments. 2. Many leading brands in the ORS, Ophthalmic, and anti-infective segments. 3. World-class, state-of-the-art manufacturing facilities. 4. Regulatory expertise to consistently meet with the standards of the most stringent regulatory bodies U.S. FDA, U.K. MKHRA, SA MCC, ANVISA, etc. 5. Cost-effective and innovative products. 6. Cutting-edge R&D infrastructure. We expect to grow steadily in the year 2006-2007. I take this opportunity to thank you all our shareowners, the medical fraternity, the consumers, our suppliers, our valuable employees and the public at large. Thank you for your support, trust and confidence in us - year after year! MOHAN A. CHANDAVARKAR June 24, 2006 Chairman and Managing Director